Citations

Clear

13603 citation(s) found for "_, _".

UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP
Tian, Shulan , Jenkinson, Garrett , Ferrer, Alejandro Tiana, Yan, Huihuang , Morales‐Rosado, Joel A. , Wang, Kevin L. , Lasho, Terra L. , Yan, Benjamin B. , Baheti, Saurabh , Olson, Janet E. , Patnaik, Mrinal M. , Klee, Eric W. , Ferrer, Alejandro , Ferrer, Alejandro , Baughn, Linda B , Ding, Wei , Slager, Susan L , Patnaik, Mrinal , Lazaridis, Konstantinos N , Klee, Eric W , Olson, Janet E , Lasho, Terra L , Tian, Shulan , Morales-Rosado, Joel A , Baughn, Linda B. , Slager, Susan L. , Lazaridis, Konstantinos N.

Mayo Clinic

Genomics, Proteomics & Bioinformatics | April 29, 2025 | Volume: 23 | Issue: 2 | Pages: No page available

10.1093/gpbjnl/qzaf040 | PMID 40300108 Get It

Abstract Clonal hematopoiesis (CH) of indeterminate potential (CHIP), driven by somatic mutations in leukemia-associated genes, confers increased risk of hematologic malignancies, cardiovascular disease, and all-cause mortality. In blood of healthy individuals, small CH clones can expand over time to reach 2% variant allele frequency (VAF), the current threshold for CHIP. Nevertheless, reliable detection of low-VAF CHIP mutations is challenging, often relying on deep targeted sequencing. Here, we present UNISOM, a streamlined workflow for enhancing CHIP detection from whole-genome and whole-exome sequencing data that are underpowered, especially for low VAFs. UNISOM utilizes a meta-caller for variant detection, in couple with machine learning models which classify variants into CHIP, germline, and artifact. In whole-exome sequencing data, UNISOM recovered nearly 80% of the CHIP mutations identified via deep targeted sequencing in the same cohort. Applied to whole-genome sequencing data from Mayo Clinic Biobank, it recapitulated the patterns previously established in much larger cohorts, including the most frequently mutated CHIP genes and predominant mutation types and signatures, as well as strong associations of CHIP with age and smoking status. Notably, 30% of the identified CHIP mutations had < 5% VAFs, demonstrating its high sensitivity toward small mutant clones. This workflow is applicable to CHIP screening in population genomic studies. The UNISOM pipeline is freely available at https://github.com/shulanmayo/UNISOM and https://ngdc.cncb.ac.cn/biocode/tool/7816.
Current State of Baseball Interval Throwing Programs: A Systematic Review of Content, Structure, and Variability of Published Throwing Programs
Iyer, Sanathan, Simon, Karissa N. , Cherny, Chad E., Johnson, Andrew , Zajac, John M., Christoffer, Daniel J., Hellem, Aaron R., Finck, Adam N., Langhans, Mark T. , Boos, Alexander M. , Johnson, Andrew J, Camp, Christopher L. , Iyer, Sanathan, Johnson, Andrew J., Johnson, Andrew

Mayo Clinic

Sports Health: A Multidisciplinary Approach | April 29, 2025 | Volume: 17 | Issue: 6 | Pages: 1214-1224

10.1177/19417381251333402 | PMID 40298098 Get It

Context: There is need for an up-to-date comprehensive review of baseball interval throwing programs in the literature. Objective: To (1) understand the origin and basis of interval throwing programs; (2) evaluate the content of programs in the peer-reviewed literature including target audience, initiation criteria, throwing specifics, arm care, and performance evaluation metrics; (3) classify these variables as well defined, ambiguous, or missing; and (4) analyze variability in key aspects including starting criteria, length, progression, and completion criteria. Data Sources: Medline, Embase, Cochrane Reviews, Web of Science, and Scopus Study Selection: The full text of studies, in English, had to be available. Included studies had to contain a complete interval throwing program designed for baseball players. Study Design: Systematic review. Level of Evidence: Level 4. Data Extraction: Initial screening was conducted based on article title and abstract. Full text of the remaining articles was evaluated for fulfillment of inclusion criteria. Results: Nine studies initially met inclusion criteria. The programs’ comprehensiveness was poor, with a mean Interval Throwing Program Checklist score of 20 (range 14-23) on a scale of 0 to 30. There were a variety of components, including progressive long toss, weighted ball, and throwing mechanics exercises. The programs identified had significant heterogeneity in duration, intensity, progression, and focus. Overall, there was a significant lack of attempts at validation or formal study of efficacy for published throwing programs. Conclusion: Current published interval throwing programs are mostly variations of an original program published many years ago and were based on principles of progressive loading with pain as sign of injury that should be monitored carefully. However, these programs have minimal clinical validation and objective measures to quantify their effectiveness. This work identifies several limitations in the current literature and can serve as a foundation for future development of evidence-based interval throwing programs.
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study
Ahmed, Kamran A. , Kim, Younchul, Kim, Sungjune, DeJesus, Michelle, Arrington, John A., Armaghani, Avan , Costa, Ricardo , Loftus, Loretta , Rosa, Marilin , Díaz, Roberto , Tran, Nam , Czerniecki, Brian J. , Yu, Hsiang-Hsuan Michael, Czerniecki, Brian J , Wang, Min , Soyano, Aixa , Caudell, Jimmy J , Etame, Arnold B. , Soliman, Hatem Hussein , Forsyth, Peter A , Han, Hyo S

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 28, 2025 | Volume: 13 | Issue: 4 | Pages: e011432

10.1136/jitc-2024-011432 | PMID 40295143 Get It

Background We hypothesized treatment with nivolumab and stereotactic radiosurgery (SRS) would be feasible, well tolerated, and may improve intracranial tumor control over SRS alone for breast cancer brain metastases (BCBM). Methods The study is a phase Ib trial of nivolumab and SRS for BCBM. Clinical trial information: NCT03807765 . Key eligibility criteria include BCBM of all subtypes, age ≥18, Eastern Cooperative Oncology Group Performace Status (ECOG-PS)≤2 with ≤10 brain metastases. Treatment was initiated with a dose of nivolumab (480 mg intravenously) that was repeated every 4 weeks. The initial dose of nivolumab was followed 1 week later by SRS. Blood was collected at baseline and every 4 weeks for flow cytometry and cell-free DNA (cfDNA) assessment. Results A total of 12 patients received SRS to 17 brain metastases. Breast cancer subtypes included triple negative (50%), hormone receptor (HR)+/HER2− (33%), and HR−/HER2+ (17%). Median follow-up from start of protocol therapy is 56 months. No cases of radionecrosis were noted. Two lesions were noted to undergo local failure, both pathologically confirmed, for a 12-month local control of 94%. Median distant intracranial control was 7.4 months with a 12-month control rate of 33%. Median systemic progression-free survival was 7.7 months with a 12-month rate of 42%. Median overall survival (OS) was 24.7 months with a 12-month OS of 75%. Most patients were noted to have an increase in cfDNA throughout study treatment, at week 5 compared with baseline (83%), week 25 compared with baseline (89%), and 100% at first follow-up. Intracranial control was associated with lower levels of CD4 regulatory T cells (Treg) (p=0.03) and higher levels of CD4 T effector memory (p=0.04). Conclusions Nivolumab and SRS is a safe and feasible treatment option in BCBM. Long-term follow-up revealed no cases of radiation necrosis. Trial registration number NCT03807765 .
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies
Jain, Michael D. , Abramson, Jeremy S. , Ansell, Stephen M. , Abramson, Jeremy S , Jain, Michael D

Mayo Clinic

American Society of Clinical Oncology Educational Book | April 28, 2025 | Volume: 45 | Issue: 3 | Pages: No page available

10.1200/edbk-25-473916 | PMID 40294348 Get It

Antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric antigen receptor (CAR) T cells are widely used standard-of-care therapies that have revolutionized the treatment of lymphoid and plasma cell malignancies. With recent regulatory approvals, these therapies are poised to also revolutionize the treatment of common solid tumors and become a part of the everyday lexicon, the ABCs, of the practicing oncologist. Drawing from experience in hematology, we review the early, late, and rare toxicities of ADCs, BsAbs, and CAR T cells and provide general principles for their management.
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Tzeng, Sheue‐Fen , Yu, Yi-Ru , Park, Jaeoh , Renesse, Janusz von , Hsiao, Huey-Wen , Hsu, Chen-Hsuan , Garnica, Josep , Chen, Jintian , Chiu, Lu-Ting , Santol, Jonas , Chen, Tse-Yu , Chung, Pei-Han , Meng, Zhen , Lin, Yun-Han, Tsai, Chin‐Hsien , von Renesse, Janusz , Kandalaft, Lana E , Starlinger, Patrick , Hsieh, Rodney Cheng-En , Yu, Ming-Chin , Hsiao, Pei-Wen , Carmona, Santiago J , Chen, Hung-Kai , Meng, Zhen , Lin, Yun-Han , Zhou, Jingying , Tsai, Chin-Hsien , Ho, Ping-Chih , Santol, Jonas , Starlinger, Patrick , Hsieh, Cheng‐En

Mayo Clinic

Cancer Discovery | April 28, 2025 | Volume: 15 | Issue: 8 | Pages: 1676-1696

10.1158/2159-8290.cd-24-1409 | PMID 40294022 Get It

Abstract Tumor cells develop various strategies to evade immune surveillance, one of which involves altering the metabolic state of the tumor microenvironment. In response to metabolic stress in the tumor microenvironment, several tumor-infiltrating immune subsets upregulate CD36 to take up lipids. This leads to impaired antitumor immunity, as intratumoral regulatory T cells exhibit increased survival and suppressive activity, whereas CD8+ T cells become more susceptible to ferroptosis and exhaustion. In this study, we develop a humanized anti-CD36 IgG4 antibody, PLT012, against the lipid-binding domain of CD36 with excellent safety and favorable pharmacokinetic features in mice and cynomolgus monkeys. PLT012 alone or in combination with PD-L1 blockade or standard-of-care immunotherapy results in robust antitumor immunity in both immunotherapy-sensitive and -resistant hepatocellular carcinomas (HCC). Notably, PLT012 also reprograms the immune landscape of human HCC ex vivo. Our findings provide proof-of-concept evidence that PLT012 reprograms antitumor immunity in HCC, positioning it as a first-in-class immunotherapy targeting CD36. Significance: Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.
Key Resting Echocardiographic Parameters for the Estimation of Exercise Parameters of Peak VO2, Heart Rate Recovery, and Ventilatory Efficiency
Chaliki, Kalyan , Sharma, Arundhati , Yee, Claire , Chaliki, Hari P. , Reddy, Satyajit , Sharma, Anubhuti , Yee, Claire , Chaliki, Hari, Reddy, Satyajit

Mayo Clinic

Journal of Clinical Medicine | April 28, 2025 | Volume: 14 | Issue: 9 | Pages: 3013

10.3390/jcm14093013 | PMID 40364045 Get It

Background/Objectives: The peak oxygen consumption (VO2) during cardiopulmonary exercise testing (CPET) is a strong predictor of all-cause mortality. The cardiac output, a key determinant of VO2, can be assessed using resting echocardiographic parameters. The heart rate recovery and ventilatory efficiency (VE/VCO2 slope) from CPET offer additional insights into cardiovascular fitness. Methods: This study aimed to identify resting echocardiographic parameters that predict the percentage of predicted peak VO2, heart rate recovery, and VE/VCO2 slope in a general cardiology population. This retrospective analysis included 1909 patients who underwent echocardiography within 3 months of CPET from 2017 to 2022. Patients with potentially confounding co-morbid conditions were removed. Spearman correlations were used to compare 19 echocardiographic parameters to peak VO2, heart rate recovery, and the VE/VCO2 slope, followed by multiple linear regression of peak VO2. Results: Eleven echocardiographic parameters correlated with peak VO2, with the strongest correlations seen with the left ventricular stroke volume index (R = 0.284, p < 0.001), mitral valve medial annular a’ wave velocity (R = 0.142, p < 0.0001), and mitral E-to-e’ ratio (R = −0.117, p < 0.0001). The left ventricular diastolic parameters and mitral E/A ratio correlated strongly with the heart rate recovery and VE/VCO2 slope. The multiple linear regression analysis identified the left ventricular mass index, stroke volume index, mitral valve E wave velocity, tricuspid valve regurgitation peak systolic velocity, tricuspid lateral annular systolic velocity S’, and left atrial volume index as independent predictors of peak VO2 (R2 = 0.191). Conclusions: The left ventricular stroke volume, diastolic function, and RV systolic function markers are significant predictors of cardiopulmonary fitness, aiding clinical decision-making in patients without CPET data.
Author response: Follicular helper- and peripheral helper-like T cells drive autoimmune disease in human immune system mice
Vecchione, Andrea, Danzl, Nichole , Li, Hao Wei , Nauman, Grace , Madley, Rachel, Winchester, Robert , Ruiz, Amanda , Ding, Xiaolan, Sykes, Megan , Khosravi-Maharlooei, Mohsen , Waffarn, Elizabeth , Fousteri, Georgia

Mayo Clinic

No container title available | April 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.99389.3.sa3 Get It

Follicular helper- and peripheral helper-like T cells drive autoimmune disease in human immune system mice
Khosravi-Maharlooei, Mohsen, Vecchione, Andrea, Danzl, Nichole , Li, Hao Wei , Nauman, Grace , Madley, Rachel, Winchester, Robert , Ruiz, Amanda , Ding, Xiaolan, Sykes, Megan , Khosravi-Maharlooei, Mohsen , Ruiz, Amanda , Khosravi-Maharlooei, Mohsen , Waffarn, Elizabeth , Fousteri, Georgia

Mayo Clinic

eLife | April 28, 2025 | Volume: 13 | Issue: No issue available | Pages: No page available

10.7554/elife.99389.3 Get It

Human immune system (HIS) mice constructed in various ways are widely used for investigations of human immune responses to pathogens, transplants, and immunotherapies. In HIS mice that generate T cells de novo from hematopoietic progenitors, T cell-dependent multisystem autoimmune disease occurs, most rapidly when the human T cells develop in the native NOD.Cg- Prkdc scid Il2rg tm1Wjl (NSG) mouse thymus, where negative selection is abnormal. Disease develops very late when human T cells develop in human fetal thymus grafts, where robust negative selection is observed. We demonstrate here that PD-1 + CD4 + peripheral (Tph) helper-like and follicular (Tfh) helper-like T cells developing in HIS mice can induce autoimmune disease. Tfh-like cells were more prominent in HIS mice with a mouse thymus, in which the highest levels of IgG were detected in plasma, compared to those with a human thymus. While circulating IgG and IgM antibodies were autoreactive to multiple mouse antigens, in vivo depletion of B cells and antibodies did not delay the development of autoimmune disease. Conversely, adoptive transfer of enriched Tfh- or Tph-like cells induced disease and autoimmunity-associated B cell phenotypes in recipient mice containing autologous human APCs without T cells. Tfh/Tph cells from mice with a human thymus expanded and induced disease more rapidly than those originating in a murine thymus, implicating HLA-restricted T cell-APC interactions in this process. Since Tfh, Tph, autoantibodies, and lymphopenia-induced proliferation (LIP) have all been implicated in various forms of human autoimmune disease, the observations here provide a platform for the further dissection of human autoimmune disease mechanisms and therapies.
Delirium prevalence, interventions and barriers in intensive care units in German‐speaking countries: A retrospective cross‐sectional secondary analysis
Exl, Matthias Thomas , Fischbacher, Sibylle, Liu, Keibun , Hoffmann, Magdalena , Nydahl, Peter, Haken, Rebecca von , Schimböck, Florian , Group, the WDAD Study, Olotu, Cynthia , Jeitziner, Marie-Madlen , Lindroth, Heidi , Jeitziner, Marie‐Madlen , Nydahl, Peter , Krüger, Lars , Group, the WDAD Study

Mayo Clinic

Nursing in Critical Care | April 28, 2025 | Volume: 30 | Issue: 3 | Pages: No page available

10.1111/nicc.70041 | PMID 40289504 Get It

Abstract Background The prevalence of delirium in intensive care units (ICUs) is high and has a major impact on patient outcomes. Aim To describe delirium assessment instruments, prevalence, interventions and barriers in delirium management in adult and paediatric ICUs; and to explore the association between delirium prevalence and reported interventions and barriers at unit level. Study Design A secondary analysis of the cross‐sectional World Delirium Awareness Day Delirium Survey on 15 March 2023. This was a prospective study to assess the one‐day point delirium prevalence, practices and quality improvement efforts across healthcare systems. Data was analysed descriptively and using multiple linear regression. Results Data of 1612 assessments in 123 ICUs from three German‐speaking countries were analysed. The most frequently used delirium assessment instrument was the Intensive Care Delirium Screening Checklist (43.9%, n = 54). The prevalence of delirium at 8 AM was 18.6% and at 8 PM 20.4% from the 94 ICUs included in the regression analyses. Prevalence for adult and paediatric and mixed ICUs are comparable. Main reported over all unit‐level interventions were ‘pain management’ (95.9%, n = 118), ‘mobilization’ (94.3%, n = 116) and ‘verbal re‐orientation’ (84.6%, n = 104). Main reported over all unit‐level barriers were ‘shortage of staff’ (53.7%, n = 66) and ‘patients who are difficult to assess’ (44.7%, n = 55). Interventions such as ‘avoidance of bladder tubes/catheters’ in all ICUs, ‘use of ear plugs and/or sleep glasses’ in adult ICUs and ‘mobilization’ in paediatric and mixed ICUs were associated with reduced delirium prevalence. Across all ICUs, as well as in both adult and paediatric ICUs, ‘lack of appropriate scores for delirium assessment’ was identified as a significant barrier. Conclusions One fifth of assessed ICU patients suffer from delirium. Several reported unit‐level interventions and barriers may have an impact on delirium prevalence, suggesting an approach for future studies and clinical practice. Relevance to Clinical Practice In clinical practice, unit‐level ‘avoidance of bladder tubes/catheters’, ‘use of ear plugs and/or sleep glasses’ and ‘mobilization’ may be used as delirium prevention and treatment interventions.
The fetal myocardial fulcrum: echocardiographic study, functional evaluation, gross anatomy and histology
Olavarría, Alberto Sosa , Yániz, Reigosa, Peña, Martí, Peralta, Zurita, Giugni, Schenone, Ramírez, Alcedo, Peña, Martí, Ramírez, Alcedo

Mayo Clinic

No container title available | April 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.174565465.58761923/v1 Get It

Objective: The fulcrum as a structure that has been described in human and mammalian hearts as ossa cordis; the aim of the present study is to demonstrate its existence in the fetal heart, using ultrasonographic techniques and macro and microscopic anatomy. Methods: Ultrasound images of the fulcrum were obtained in 240 normal fetal hearts between 26 and 37 weeks of gestation, using 2D ultrasound and TM mode in 201 cases. Speckle tracking alone was used in 58 cases to demonstrate the triphasic movements of the fulcrum. Macroscopic anatomical dissection and histological study were performed in eight fetal hearts from spontaneous abortions (20-22 weeks). Results: We demonstrated the presence of the cardiac fulcrum, on which myocardial tissue fibers are inserted as a tendon constituting a unit that serves as a pivot for cardiac contraction, resulting in a three-phase displacement of the fulcrum. Values and displacement curves were obtained as a function of gestational age, adjusted to the cubic regression model and bivariate correlation (p < 0.001). Macroscopic anatomy and histology results are presented. Conclusions: The present study demonstrated the myocardial fulcrum in the fetal heart, a structure composed of myxo-chondroid tissue, being able to be visualized by ultrasound. This structure that acts as a lever has a mixed displacement that can be quantified in terms of vertical, rotational, angular and deformation displacement. Its existence could be proved in macro and histological dissections demonstrating the anchorage of cardiac fibers at the ends of this structure.